What is the most accurate statement regarding testosterone therapy and prostate cancer risk?

Testosterone therapy and its relationship to prostate cancer risk is a nuanced topic in medical research. Monitoring prostate-specific antigen (PSA) levels is an essential aspect of the evaluation process before and during testosterone therapy.

Before initiating testosterone therapy, a baseline PSA level should be measured to assess the patient’s risk for prostate cancer. Continuous monitoring of PSA levels annually or even more frequently is recommended because testosterone can stimulate prostate tissue and potentially increase the PSA levels. Thus, having regular PSA checks allows healthcare providers to detect any significant changes that could indicate an increased risk of prostate cancer or the presence of prostate cancer itself.

This practice is grounded in ensuring the safety of the patient receiving testosterone therapy, as elevated PSA levels may necessitate further investigation. Consequently, the need for a PSA before starting testosterone therapy and ongoing monitoring reflects a proactive approach to manage and assess prostate cancer risk effectively.

Other options, while they may pertain to testosterone therapy, do not accurately encapsulate the critical role of PSA monitoring in risk assessment for prostate cancer.